Shares in Geron have almost doubled in after-hours trading after the FDA’s Oncological Drugs Advisory Committee (ODAC) voted by 12 to 2 in favour of its imetelstat therapy
Geron could have a tougher time than it anticipated at tomorrow’s FDA advisory committee meeting for myelodysplastic syndromes (MDS) drug candidate imetelstat.
More than 30 years after it was first formed, Geron is on the cusp of bringing its first product to market, after imetelstat hit the mark in a phase 3 trial in patients with myelodysplastic
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.